Short-term efficacy and safety of sintilimab combined with oxaliplatin and capecitabine as neoadjuvant therapy for locally advanced gastric cancer
Journal Title: Chinese Journal of Clinical Research - Year 2025, Vol 38, Issue 1
Abstract
"<b>Objective</b> To investigate the short-term efficacy and safety of sintilimab combined with oxaliplatin and capecitabine(CapeOX) chemotherapy as neoadjuvant therapy for locally advanced gastric cancer. <b>Methods</b> From January 2019 to December 2020, 51 patients with locally advanced gastric cancer undergoing neoadjuvant therapy in the First Affiliated Hospital of Hebei North University were retrospectively analyzed. Twenty-four patients treated with sintilimab combined with CapeOX chemotherapy were the experimental group, and 27 patients treated with CapeOX chemotherapy were the control group. After evaluation, all patients underwent open or laparoscopic radical gastrectomy. Pathological tumor downstaging, tumor regression grade (TRG), pathological complete response rate (pCR) and major pathological response rate (MPR) were evaluated in the two groups, and adverse reactions were observed. <b>Results</b> The total downstaging rate of T stage and MPR in experimental group were higher than those in control group, but with no statistically significant difference (62.50%vs 40.74%,χ2= 2.407,P= 0.121; 25.00%vs 3.70%,χ2 3.231,P=0.072), while the total downstaging rate of N stage was significantly higher than that of control group (75.00%vs 37.03%,χ2 7.396,P=0.007). The experimental group surpassed the control group in evaluation of TRG (Z=2.444,P=0.015), among which 4 cases in the experimental group reached pCR(TRG 0 grade) and 0 case in the control group. There were no grade 4 adverse reactions occurred, and no significant difference was found in the incidence of adverse reactions between the two groups (P＞0.05). The incidence of immune-related adverse reactions in the experimental group was not high, and all of them were grade 1-2, which improved after symptomatic and supportive treatment. <b>Conclusion</b> Sintilimab combined with CapeOX chemotherapy as neoadjuvant therapy for patients with locally advanced gastric cancer can reduce the local tumor N stage, optimize the postoperative pathological TRG, which is conducive to improving the short-term efficacy of patients, and is safe and controllable."
Authors and Affiliations
ZHANG Shuai, LIU Liangliang, HUANG Di, SHENG Ru, DU Xuetao, LI Shuguang, HU Nan, ZHAO Yifeng
Keywords
Related Articles
- EP ID EP759888
- DOI -
- Views 12
- Downloads 0
Laparoscopic hepatectomy and open hepatectomy in treatment of hepatocellular carcinoma
Objective To explore the perioperative situation of patients with hepatocellular carcinoma (HCC) treated with laparoscopic hepatectomy or open hepatectomy and their effects on liver function. Methods A retrospective anal...
Clinical significance and research progress of microsatellite instability in gastric cancer
The occurrence and development of gastric cancer (GC) is determined by many factors. In recent years, the development of molecular biology has provided new ideas for the diagnosis and treatment of GC. Microsatellite inst...
Correlation between triglyceride-glucose index and atherosclerosis in type 2 diabetes mellitus
Objective To investigate the the clinical application of triglyceride-glucose (TyG) index and its correlation with atherosclerosis in patients with type 2 diabetes mellitus (T2DM). Methods From January 2020 to December...
Safety and feasibility analysis of indocyanine green guided preservation of upper rectal vessels in laparoscopic radical resection of sigmoid cancer
Objective To investigate the safety and feasibility of indocyanine green guided preservation of the superior rectal artery in patients undergoing laparoscopic radical resection for sigmoid cancer. Methods A total of 73 p...
Expression levels and clinical significance of NLRP3 and HMGB1 derived from platelets in patients with gout
"<b>Objective</b> To investigate the expression levels of NOD-like receptor family pyrin domain-containing 3 (NLRP3) and high mobility group box-1 proten (HMGB1) in platelets derived from patients with gout, as well as t...